Jyoti Madhusoodanan

1 month ago | healthjournalism.org | Jyoti Madhusoodanan

Several prescription medications bear FDA-approved, race-specific labels that suggest certain racial or ethnic groups should receive lower doses or may be at greater risk of side effects. And guidelines to physicians, which are endorsed by professional societies, sometimes recommend prescribing certain drugs differently based on race or ethnicity. Race-based labels exist for drugs to treat heart disease, various cancers, epilepsy, tuberculosis and other diseases.

1 month ago | undark.org | Jyoti Madhusoodanan

In June 2021, 63-year-old Lisa Daurio was making the two-hour drive from her hometown of Pueblo, Colorado, to a doctor’s appointment in Denver when she settled on a life-changing decision: She would tell her doctor she was ready to stop taking her weekly injections to treat her multiple sclerosis. Daurio was not cured, but her condition had remained stable for more than a decade. As she got older, her doctor had periodically asked if she wanted to consider halting her medication.

2 months ago | healthjournalism.org | Jyoti Madhusoodanan |Katie Burke

The U.S. National Institutes of Health, like many federal agencies, has experienced unprecedented restrictions on their operations in the new administration’s first week, including a communications pause that abruptly halted meetings and workshops, a hiring freeze, and a moratorium on travel. Industries and sectors connected to the biomedical sciences are experiencing concern and disarray as NIH funding and research processes have stopped.

Jan 15, 2025 | healthjournalism.org | Jyoti Madhusoodanan

More than 40 percent of journalists dealt with threats and online harassment in 2022. When policymakers turn their attention to science and health issues such as vaccination, access to abortion care, and the health dangers of climate change, journalists covering these topics must be prepared to protect themselves amidst online communities that can mirror — or amplify — harmful rhetoric.

Jan 2, 2025 | healthjournalism.org | Lara Salahi |Jyoti Madhusoodanan

Walgreens is now conducting a COVID-19 vaccine study at 20 locations across eight states, aiming to recruit 3,600 participants as part of a partnership with the U.S. government that will allow retail pharmacies to conduct clinical trials. Traditionally, these studies happen at academic centers, which can feel distant or inaccessible for many.